Publications by authors named "Natalia Maverakis"
Article Synopsis
- Mutations in melanoma are common and associated with a poorer prognosis, but their influence on the effectiveness of immune checkpoint inhibitors (ICIs) is still unclear.
- A comprehensive literature review analyzed studies of patients with melanoma to determine the objective response rate (ORR) to ICIs based on mutational status.
- The results showed that -mutant melanoma had a higher likelihood of responding to ICIs compared to -wildtype melanoma, suggesting that genomic screening could help predict better treatment outcomes.
Psoriatic arthritis (PsA) is a large volume of our clinical practice and its management can be challenging. Traditional DMARDs have been used over last six decades and observational studies have substantiated an effective use of many of these drugs. However, in last two decades use of anti-TNF agents has brought a new dimension in treatment of PsA and in many other autoimmune diseases.
View Article and Find Full Text PDFPsoriasis (PsO) and psoriatic arthritis (PsA) are chronic immune-mediated inflammatory diseases of multifactorial etiology. In addition to genetic and environmental factors, evidence supports involvement of a dysregulated human microbiome in the pathogenesis of psoriatic disease. In particular, alterations in the composition of the microbiome, termed dysbiosis, can result in downstream proinflammatory effects in the gut, skin, and joints.
View Article and Find Full Text PDFThe BRCA1-BRCA2-RAD51 axis is essential for homologous recombination repair (HRR) and is frequently disrupted in breast cancers. PARP inhibitors (PARPis) are used clinically to treat BRCA-mutated breast tumors. Using a genetic screen, we identified EMI1 as a modulator of PARPi sensitivity in triple-negative breast cancer (TNBC) cells.
View Article and Find Full Text PDF